×
About 35,090 results

ALLMedicine™ Neutropenia Center

Research & Reviews  8,408 results

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative ch...
https://doi.org/10.1097/MD.0000000000033271
Medicine Yeon SH, Lee MW et. al.

Mar 18th, 2023 - The aim of this study was to assess the therapeutic efficacy of a cisplatin and vinorelbine combination as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer. We retrospectively reviewed the medical records of ...

Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of...
https://doi.org/10.1093/bjd/ljad038
The British Journal of Dermatology; Pathmarajah P, Corso R et. al.

Mar 18th, 2023 - Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.|2023|Pathmarajah P,Corso R,Salam A,Shah G,Woolf R,|

Valproate-related neutropenia and lithium-related leukocytosis in patients treated with...
https://doi.org/10.1186/s12888-023-04659-2
BMC Psychiatry; Yang CC, Wang XY et. al.

Mar 17th, 2023 - Neutropenia is a noteworthy side effect of clozapine, which might warrant this drugs' discontinuance for safety. Studies have revealed that the risk of neutropenia increases with concurrent administration of valproate, but the evidence was limited...

Hermansky-Pudlak Syndrome - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/hps/

Mar 16th, 2023 - Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, a bleeding diathesis, and, in some individuals, pulmonary fibrosis, granulomatous colitis, and/or immunodeficiency. Ocular findings include nystagmus, reduced iris pigmen...

Validation of National Early Warning Score (News) and Quick Sequential (Sepsis-Related)...
https://doi.org/10.1111/ejh.13952
European Journal of Haematology; Frairia C, Nicolino B et. al.

Mar 16th, 2023 - Chemotherapy-induced neutropenia in acute myeloid leukaemia (AML) is a risk factor for life-threatening infections. Early diagnosis and prompt interventions are associated with better outcomes, but the prediction of infection severity remains an o...

see more →

Guidelines  16 results

Emerging challenges in the evaluation of fever in cancer patients at risk of febrile ne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682766
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Font C et. al.

Nov 25th, 2020 - Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 ...

Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
https://doi.org/10.1210/clinem/dgaa543
The Journal of Clinical Endocrinology and Metabolism; Brar PC, Heksch R et. al.

Aug 19th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain.
https://doi.org/10.1016/j.jacr.2018.09.010
Journal of the American College of Radiology : JACR; , Scheirey CD et. al.

Nov 6th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASC...
https://doi.org/10.1200/JCO.18.00374
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Sep 5th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: Americ...
https://doi.org/10.1200/JCO.2017.77.6211
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Feb 21st, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

see more →

Drugs  459 results see all →

Clinicaltrials.gov  810 results

Comparison of Uncomplicated Candidemia Therapy Duration in Children
https://clinicaltrials.gov/ct2/show/NCT05763251

Mar 10th, 2023 - The primary objective of this study will be addressed with a multi-center open label randomized controlled trial designed to compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-...

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04851613

Mar 9th, 2023 - Eligible patients for this study must have either (1) progressive disease whilst receiving an endocrine therapy (AI or a SERM), and/or a CDK4/6 inhibitor for locally advanced or metastatic disease; or (2) relapsed with metastatic disease whilst re...

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
https://clinicaltrials.gov/ct2/show/NCT02991456

Mar 8th, 2023 - All eligible subjects should receive a planned total dose of 54-60 gray (GY) of radiation and 75 mg/m2 of TMZ daily for a total of six weeks. Patients will be randomized to receive one of two antiemetic treatment sequences: sequence A that involve...

Cancer in Inherited Bone Marrow Failure Syndromes
https://clinicaltrials.gov/ct2/show/NCT00027274

Mar 7th, 2023 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Oral Complications in Hematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT05758207

Mar 7th, 2023 - Oral lesions can be the first presentation of hematological malignancy. Dentists occasionally are the first healthcare provider that detect oral signs related to a systemic condition and thus contribute to the early diagnosis of the disease 1. Ora...

see more →

News  4,332 results

CLL treatment: More infections among real-world patients
https://www.mdedge.com/hematology-oncology/article/261615/cll/cll-treatment-more-infections-among-real-world-patients
Randy Dotinga

Mar 6th, 2023 - A new real-world analysis finds that severe infection rates were higher than in clinical trials in 67 patients with chronic lymphocytic leukemia (CLL) or B-cell lymphoma who took ibrutinib (Imbruvica), idelalisib (Zydelig), or venetoclax (Venclext.

Commentary: Evaluating first-line regimens in breast cancer, March 2023
https://www.mdedge.com/hematology-oncology/article/261531/breast-cancer/commentary-evaluating-first-line-regimens-breast
Erin Roesch, MD

Mar 1st, 2023 - Erin Roesch, MD The KEYNOTE-522 study has established a regimen of carboplatin/paclitaxel/pembrolizumab followed by doxorubicin/cyclophosphamide/pembrolizumab as standard neoadjuvant therapy for early-stage triple-negative breast cancer (TNBC). Th.

Neoadjuvant chemotherapy with nab-paclitaxel+pembrolizumab shows encouraging pCR rates in TNBC
https://www.mdedge.com/hematology-oncology/article/261435/breast-cancer/neoadjuvant-chemotherapy-nab

Feb 24th, 2023 - Key clinical point: Neoadjuvant chemotherapy (NACT) with nab-paclitaxel plus pembrolizumab followed by epirubicin/cyclophosphamide demonstrated encouraging pathological complete response (pCR) rates and an acceptable safety profile in patients wit.

CAR-T Makes Its Case for Earlier Use in Multiple Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/103065

Feb 10th, 2023 - Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel; Abecma) significantly improved outcomes in patients with triple-class-exposed, relapsed and refractory multiple myeloma, according to the phase III KarMMa-3 trial...

Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/102964

Feb 3rd, 2023 - Adding docetaxel to radiation therapy (RT) improved survival outcomes in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase III randomized trial showed. At a median follow-up of 32.4 months, the 2-ye...

see more →

Patient Education  11 results see all →